Interval Partners LP Invests $49.59 Million in Ralliant Corporation $RAL

Key Points

• Interval Partners LP acquired 1,133,949 shares of Ralliant (~$49.59M), representing about 1.01% of the company and roughly 0.8% of Interval's portfolio (its 26th largest holding).
• Ralliant beat estimates with Q results of EPS $0.69 (vs. $0.67 est.) and revenue $554.6M (vs. $543.0M est.), and issued Q1 2026 guidance of $0.460–0.520 and FY 2026 guidance of $2.220–2.420; the stock has a market cap of $4.73B and a PE of 21.6.
• The company declared a quarterly dividend of $0.05 per share (annualized $0.20, ~0.5% yield) while insiders showed mixed activity (a director bought shares and an SVP sold), and analysts maintain a consensus "Hold" with a $50.50 target.

Interval Partners LP acquired a new stake in Ralliant Corporation (NYSE:RAL - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,133,949 shares of the company's stock, valued at approximately $49,588,000. Ralliant comprises about 0.8% of Interval Partners LP's investment portfolio, making the stock its 26th biggest position. Interval Partners LP owned approximately 1.01% of Ralliant as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Westfuller Advisors LLC acquired a new position in Ralliant in the third quarter valued at $26,000. Manchester Capital Management LLC bought a new stake in Ralliant during the second quarter valued at $29,000. UMB Bank n.a. acquired a new stake in Ralliant during the 3rd quarter worth about $29,000. BOKF NA acquired a new stake in Ralliant during the 3rd quarter worth about $29,000. Finally, Webster Bank N. A. bought a new position in shares of Ralliant in the 3rd quarter worth about $31,000.

Ralliant Stock Performance

Shares of RAL opened at $42.34 on Friday. Ralliant Corporation has a one year low of $37.27 and a one year high of $57.02. The company has a market cap of $4.73 billion and a PE ratio of 21.60. The stock has a 50-day moving average of $48.24 and a 200-day moving average of $46.69. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The firm's quarterly revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant's dividend payout ratio is presently 10.20%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on RAL shares. Barclays cut their target price on Ralliant from $60.00 to $52.00 and set an "overweight" rating on the stock in a research report on Monday, February 9th. Vertical Research raised Ralliant from a "hold" rating to a "buy" rating and set a $45.00 price target on the stock in a research note on Friday, February 6th. Weiss Ratings cut Ralliant from a "hold (c)" rating to a "sell (d)" rating in a report on Thursday, February 5th. Truist Financial lowered their price objective on shares of Ralliant from $62.00 to $49.00 and set a "buy" rating for the company in a research note on Friday, February 6th. Finally, Zacks Research downgraded shares of Ralliant from a "hold" rating to a "strong sell" rating in a research report on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $50.50.

Insider Buying and Selling

In other Ralliant news, Director Kate Mitchell purchased 2,350 shares of the firm's stock in a transaction on Tuesday, February 10th. The stock was acquired at an average price of $42.48 per share, for a total transaction of $99,828.00. Following the purchase, the director owned 8,411 shares of the company's stock, valued at $357,299.28. This trade represents a 38.77% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Karen M. Bick sold 5,485 shares of the company's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the transaction, the senior vice president owned 46,756 shares in the company, valued at approximately $2,104,020. The trade was a 10.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders purchased 8,145 shares of company stock worth $332,233 over the last quarter.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.